comparemela.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) CEO Christopher Gibson sold 33,073 shares of the firm’s stock in a transaction dated Wednesday, May 3rd. The stock was sold at an average price of $4.71, for a total transaction of $155,773.83. Following the sale, the chief executive officer now directly owns 953,225 shares in the company, […]

Related Keywords

Christopher Gibson ,Vanguard Group Inc ,Recursion Pharmaceuticals Company Profile ,Blackrock Inc ,Quarter For Recursion Pharmaceuticals ,Needham Company ,Recursion Pharmaceuticals ,Nasdaq ,Recursion Pharmaceuticals Trading ,Baillie Gifford Co ,News Ratings For Recursion Pharmaceuticals Daily ,Recursion Pharmaceuticals Inc ,Institutional Trading Of Recursion Pharmaceuticals ,Get Rating ,Laurion Capital Management ,Capital Management ,Recursion Pharmaceuticals Daily ,Nasdaq Rxrx ,Rxrx ,Medical ,Insider Trading ,Nsider Trades ,Stocks ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.